Browse the evidence

A specific missense variant in the GIP receptor (GIPR, rs1800437, p.Glu354Gln) is associated with an increased risk of vomiting in patients treated with tirzepatide, but not semaglutide.

If you are taking tirzepatide (Mounjaro/Zepbound), your genetics can influence your risk of vomiting. A specific variant in the GIP receptor (rs1800437) is linked to a higher risk of vomiting. This is specific to tirzepatide because it targets both GLP-1 and GIP receptors. If you experience severe vomiting, discussing your genetic history or considering alternative therapies might be beneficial, as this genetic factor does not affect semaglutide users.

Recent safety data from the SELECT trial indicates a higher incidence of hip and pelvic fractures in female patients and those aged 75+ taking semaglutide 2.4 mg weekly compared to placebo.

If you are over 75 or a postmenopausal woman taking semaglutide for heart health, be aware that your risk of hip or pelvic fractures may be slightly higher than if you were not taking the drug. This risk is likely linked to the weight and muscle loss. Ensure you are doing strength training, getting enough calcium/Vitamin D, and discussing bone density scans (DEXA) with your doctor.

Pharmacologic activation of GIP and GLP-1 receptors rapidly inhibits AgRP neurons, and this neural inhibition contributes to the appetite-suppressing effects of incretin-based obesity therapies.

Incretin-based medications (like semaglutide and tirzepatide) work in part by shutting down hunger-promoting brain cells (AgRP neurons). This mechanism is driven by both GIP and GLP-1 pathways, with dual-action drugs being more effective than single-action ones. This neural inhibition helps explain why these drugs successfully reduce food intake, even in individuals with obesity.

Genetically modeled dual GIPR/GLP1R agonism reduces binge drinking frequency and the risk of heavy drinking with psychiatric comorbidities.

Genetic evidence suggests that activating GLP-1 and GIP receptors (via drugs like semaglutide or tirzepatide) can reduce binge drinking and heavy drinking, especially in those with psychiatric comorbidities. This effect appears independent of general alcohol consumption (drinks per week), suggesting a specific impact on high-risk drinking patterns.

Higher adiposity (BMI) is positively associated with increased striatal dopamine tone in humans, as indicated by the differential displacement of low-affinity D2 receptor tracers.

This research suggests that higher body weight is associated with higher baseline (tonic) dopamine levels in the brain's reward centers. This may alter how rewarding food feels, potentially contributing to overeating. While this doesn't provide a direct 'fix,' it highlights that obesity is a neurochemical state, not just a willpower failure. Interventions might need to account for this altered reward sensitivity.

High out-of-pocket costs for semaglutide create a socioeconomic barrier to access, resulting in significantly lower prescription rates among low-income individuals despite them having a higher prevalence of obesity.

If you are on a limited budget, the high out-of-pocket cost of semaglutide may prevent you from accessing it, even if you have obesity. This is a systemic issue where low-income individuals are undertreated. Advocacy for reimbursement or subsidies is needed to address this inequality.

Lean individuals with Metabolic Dysfunction-Associated Fatty Liver Disease (lean-MAFLD) face a significantly higher risk of liver-related mortality compared to overweight or obese MAFLD patients, despite having equivalent metabolic profiles and similar risks for extrahepatic mortality.

If you are lean but have been diagnosed with fatty liver (MAFLD), do not assume you are safe because you are thin. Your risk of liver-related death is actually higher than that of obese patients with the same condition. Standard weight loss advice, especially rapid loss via drugs, can be dangerous for you because it strips away muscle, which your liver needs. Focus on metabolic health markers (blood pressure, glucose, lipids) and consult your doctor about treatments that preserve muscle mass rather than just focusing on weight loss.

Genetic deletion or specific knockdown of the mitochondrial protein MCJ (DnaJC15) in brown adipose tissue promotes thermogenesis and protects against diet-induced obesity through a UCP1-independent mechanism mediated by eIF2α signaling.

This research suggests that targeting the MCJ protein in fat cells could help the body burn more energy and resist weight gain, even without relying on the classic 'uncoupling' protein UCP1. While this is currently a genetic finding in mice, it points to potential future therapies for obesity that enhance metabolic rate through mitochondrial stress responses.

Resmetirom, a thyroid hormone receptor beta (THRβ) agonist, is the first FDA-approved drug specifically for MASH, demonstrating significant improvement in both steatohepatitis and fibrosis in patients with advanced liver fibrosis.

Resmetirom is the first FDA-approved drug specifically for MASH. It works by targeting thyroid hormone receptors in the liver to reduce fat and inflammation. It is particularly effective for patients with advanced fibrosis, but note that about 70% of patients may not respond. It is a valuable option for those who do not respond to GLP-1RAs or SGLT2-is, or who need liver-specific treatment.

Significant inequities exist in access to bariatric surgery in Australia, with lower rates in public hospitals, rural areas, and among males, despite similar or higher obesity prevalence in these groups.

Access to bariatric surgery in Australia is uneven, with rural residents, men, and those without private healthcare facing significant barriers. If you live in a rural area or are a man, be proactive in seeking information and support to overcome these barriers. Explore public sector options and discuss your specific situation with a healthcare provider.

Incretin therapies are associated with gastrointestinal side effects and potential risks of gallstone disease and pancreatitis, requiring careful patient selection and monitoring, particularly in those with a history of these conditions.

While incretin therapies are effective for MASH, patients should be aware of common side effects like nausea and potential risks like gallstones or pancreatitis. These risks can be managed with slow dose titration, dietary adjustments, and regular monitoring, making the therapy safe for most patients when used appropriately.

Setmelanotide, an MC4R agonist, significantly reduces hunger and improves health-related quality of life in patients with POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you or your child has a confirmed diagnosis of POMC, LEPR, or BBS-related obesity, standard diet and exercise plans are unlikely to resolve the insatiable hunger (hyperphagia) because they don't fix the underlying genetic signaling error. Setmelanotide is an approved targeted therapy that directly addresses this mechanism, significantly reducing hunger scores and improving quality of life in clinical trials. Consult a specialist in rare metabolic disorders to determine eligibility.

Leptin replacement therapy is effective for reducing hunger and weight in patients with congenital leptin deficiency (homozygous LEP variants) but is ineffective in patients with defects downstream of the leptin receptor (e.g., POMC, PC1/3, MC4R deficiencies).

Leptin injections are highly effective for the rare condition of congenital leptin deficiency, significantly reducing hunger and weight. However, they are useless for patients with other genetic causes of obesity (like POMC or MC4R defects) because the body's ability to respond to leptin is broken downstream. Genetic testing is essential before considering this therapy.

BMI is an inadequate measure of obesity because it does not distinguish between lean muscle mass and adipose tissue, leading to misclassification of metabolic health.

Don't rely on BMI alone. If you have a normal BMI but feel unwell, ask about waist circumference and metabolic health. If you have a high BMI but are muscular, focus on metabolic markers rather than just weight.

Diet and lifestyle interventions alone are insufficient for long-term obesity management, as they typically result in only ~3% sustained weight loss at 5 years and fail to reverse population-level obesity trends.

Do not rely on short-term diet and exercise programs for long-term weight control. The average outcome is minimal sustained loss (~3%). Recognize obesity as a chronic condition requiring long-term, multidisciplinary support (medical, behavioral, environmental) rather than a finite 'program' you complete.

None of the tested dietary supplements (protein, creatine, HMB) significantly increased lean body mass in athletes when combined with strength and conditioning training.

Do not expect supplements like protein, creatine, or HMB to significantly increase your muscle mass on their own. Focus on your training and overall diet. This analysis found no significant benefit for muscle mass from these supplements in trained athletes.

Genetic loss-of-function variants of the GIP receptor are associated with lower body mass index (BMI) and reduced obesity prevalence in humans.

People with certain genetic variations that reduce GIP receptor function tend to have lower body weight. This genetic insight supports the development of drugs that block GIP receptors to achieve similar weight loss benefits.

Positive Airway Pressure (PAP) therapy, while effective for reducing AHI and improving symptoms, has not demonstrated a benefit on composite cardiovascular endpoints in randomized controlled trials.

PAP is the standard treatment for OSA and effectively reduces breathing interruptions and daytime sleepiness. However, it does not appear to reduce long-term cardiovascular risks like heart attacks or strokes in large studies, and many patients struggle with adherence due to discomfort. It remains a good option for symptomatic relief and blood pressure control, but may not be a 'one-size-fits-all' solution.

Semaglutide increases the risk of non-serious gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, in patients at increased risk of cardiovascular events.

Expect stomach issues like nausea, vomiting, or diarrhea when starting semaglutide. These are common, usually get better over time, and are not considered 'serious' adverse events. Managing diet and starting with a low dose can help mitigate these effects.

High-dose tirzepatide (15mg/week) is associated with a significantly increased risk of overall gynecologic tumors compared to controls, with an odds ratio of 2.37.

If you are taking high-dose tirzepatide (15mg/week), be aware that this network meta-analysis found a statistically significant increase in gynecologic tumor risk compared to controls. The absolute risk increase is small (0.57%), but it exists. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Both high-dose (15mg/week) and low-dose (5mg/week) tirzepatide are associated with a significantly elevated risk of intra-uterus tumors.

If you are taking tirzepatide (whether 5mg or 15mg weekly), be aware that this network meta-analysis found a statistically significant increase in the risk of intra-uterus tumors. The risk appears to be present at both low and high doses. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Sleeve gastrectomy is associated with a higher risk of new-onset or worsening gastroesophageal reflux disease (GERD) compared to Roux-en-Y gastric bypass (RYGB).

If you have existing or severe acid reflux, Roux-en-Y gastric bypass is likely a safer choice than sleeve gastrectomy, as the sleeve procedure carries a higher risk of causing or worsening reflux.

Tirzepatide reduces the incidence of heart failure hospitalizations, need for treatment intensification, and mortality due to cardiovascular causes in patients with heart failure and reduced ejection fraction.

If you have heart failure and reduced ejection fraction, Tirzepatide can reduce your risk of hospitalization and cardiovascular mortality.

Metabolic/bariatric surgery (MBS) is the most cost-effective intervention for class II and III obesity, often demonstrating dominance (cost-saving) over non-surgical management.

For individuals with Class II or III obesity, metabolic/bariatric surgery is the most economically and clinically effective long-term solution, often paying for itself through reduced healthcare costs from comorbidity remission. It should be prioritized over pharmacotherapy for this group.